Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer - PubMed (original) (raw)

• KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential.
  Eser M, Hekimoglu G, Yarar MH, Canbek S, Ozcelik M. Eser M, et al. Sci Rep. 2024 Nov 4;14(1):26581. doi: 10.1038/s41598-024-75208-4. Sci Rep. 2024. PMID: 39496639 Free PMC article.
• The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis.
  Zhao R, Shu Y, Xu W, Jiang F, Ran P, Pan L, Wang J, Wang W, Zhao J, Wang Y, Fu G. Zhao R, et al. Cancer Cell Int. 2024 Nov 1;24(1):361. doi: 10.1186/s12935-024-03498-9. Cancer Cell Int. 2024. PMID: 39487476 Free PMC article. Review.
• Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer.
  Yao J, Lin X, Zhang X, Xie M, Ma X, Bao X, Song J, Liang Y, Wang Q, Xue X. Yao J, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2406063. doi: 10.1080/21645515.2024.2406063. Epub 2024 Oct 16. Hum Vaccin Immunother. 2024. PMID: 39415535 Free PMC article. Review.
• CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
  Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellm… See abstract for full author list ➔ Skoulidis F, et al. Nature. 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9. Nature. 2024. PMID: 39385035 Free PMC article.
• Dual role of Nrf2 signaling in hepatocellular carcinoma: promoting development, immune evasion, and therapeutic challenges.
  Gan L, Wang W, Jiang J, Tian K, Liu W, Cao Z. Gan L, et al. Front Immunol. 2024 Sep 2;15:1429836. doi: 10.3389/fimmu.2024.1429836. eCollection 2024. Front Immunol. 2024. PMID: 39286246 Free PMC article. Review.